global Cardiac Guidewire and Catheters Market size was valued at USD 12.14 billion in 2020 and is expected to expand at a compound annual growth rate CAGR of 7.5% from 2021 to 2027. Cardiovascular diseases are one of the leading diseases worldwide. According to Center for Disease Control and Prevention, about 610,000 die every year because of heart diseases in the United States alone. Cardiac guidewires and catheters are used to diagnosis and prevention of the cardiac diseases and process are known as cardiac catheterization. Catheters are usually hallowed flexible tube that can be inserted into a body cavity, duct or vessel. Catheters allow injecting fluids, distend a passageway for surgical instruments. Guide wires are stainless steel or metallic alloys that guide the cardiac catheter for placement. The Cardiac Guidewire and Catheters Market expected to grow at significant rate owing to increase in the prevalence of cardiovascular diseases. According to CDC, heart disease is the leading cause of death for both men and women. More than half of the deaths caused due to heart disease in 2009 were in men. In addition, factors such as, increase in awareness about different cardio devices, less traumatic surgical experience, reduced hospital stay, and faster recovery are expected to boost the global cardiac guidewire and catheters market over the forecast period. However, high cost, lack of experienced healthcare professionals, and recent product recalls are hindering the cardiac guide wire and catheters market. Global cardiac guidewire and catheters market is expected to grow at a notable rate during the forecast period owing to increased tobacco usage and lifestyle changes such as intake of high-fat food. According to Centers for Diseases Control and Prevention, (CDC) secondhand smoke causes nearly 34,000 early deaths from coronary artery disease each year in the United States among the non-smokers. The market competition is expected to grow higher with the rise in technological innovation and mergers and acquisition activities. Moreover, many local and regional vendors are offering specific application products for varied end-users. For instance, in December 2014, Abbott laboratories acquired, an electrophysiology technology company Topera, Inc., by this acquisition enabled Abbott entered into catheter-based electrophysiology market. In March 2017, U.S. Food and Drug Administration (FDA) approved Abbott’s new sensor-enabled FlexAbility ablation catheter, designed to work with EnSite Precision cardiac mapping system and MediGuide Technology to safely treat atrial flutter (condition similar to atrial fibrillation) and heart rhythm disorder.